A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition.
机构：[1]Department of Oncology, 162698The First Affiliated Hospital of Jinan University, Guangzhou, China.[2]Department of Oncology, 71537Jiangmen Central Hospital, Jiangmen, China.[3]Department of Traditional Chinese Medicine, 144991Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.中山大学附属第三医院[4]Department of Surgery, 71537Jiangmen Central Hospital, Jiangmen, China.[5]School of Life Sciences, 1994University of Technology Sydney, Sydney, NSW, Australia.[6]Centre Laboratory, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Objectives: To investigate the underlying mechanisms of how the basic fibroblast growth factor monoclonal antibody (bFGFmAb) attenuates cisplatin (DDP) resistance in lung cancer using A549 cells and cisplatin-resistant A549 cells (A549/DDP). Methods: Cancer cell proliferation, cell viability, and 50% inhibitory concentration (IC50) of cisplatin were assessed. Transwell assays were utilized to evaluate the invasion activity of tumor cells in response to treatment. Epithelial-to-mesenchymal transition markers and drug resistance proteins were analysed using Western blots. Results: We demonstrate that the bFGFmAb inhibits the proliferation and invasion of both A549 and A549/DDP cells. The bFGFmAb increases cisplatin sensitivity of both A549 and A549/DDP cells as evidenced by an increase in the IC50 of cisplatin in A549 and A549/DDP cells. Furthermore, bFGFmAb significantly increases the expression of E-cadherin, whilst decreasing the expression of N-cadherin and bFGF in both cell lines, thereby showing inhibition of epithelial-to-mesenchymal transition. In addition, we demonstrate that bFGFmAb significantly reduces the expression of the lung resistance protein. Conclusions: Our data suggests that the humanized bFGFmAb is a promising agent to attenuate cisplatin resistance in NSCLC. The underlying mechanism for this effect of bFGFmAb may be associated with the inhibition of epithelial-to-mesenchymal transition and reduced expression of lung resistance protein.
基金：
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article: This
study is supported by Guangzhou Municipal Science and Technology
Bureau (201803010059) and National Natural Science
Foundation of China (81774376).
第一作者机构：[1]Department of Oncology, 162698The First Affiliated Hospital of Jinan University, Guangzhou, China.[2]Department of Oncology, 71537Jiangmen Central Hospital, Jiangmen, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Oncology, 162698The First Affiliated Hospital of Jinan University, Guangzhou, China.[3]Department of Traditional Chinese Medicine, 144991Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.[5]School of Life Sciences, 1994University of Technology Sydney, Sydney, NSW, Australia.[6]Centre Laboratory, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.[*1]School of Life Sciences, University of Technology Sydney, PO Box 123, Broadway NSW 2007, Australia.[*2]Department of Oncology, The First Affiliated Hospital of Jinan University, 613 Huangpu Avenue West, Guangzhou 510632, China.
推荐引用方式(GB/T 7714)：
Hu Penghui,So Kaman,Chen Hongjie,et al.A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition.[J].INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY.2022,36:doi:10.1177/03946320221105134.
APA：
Hu Penghui,So Kaman,Chen Hongjie,Lin Qimou,Xu Meng&Lin Yiguang.(2022).A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition..INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY,36,
MLA：
Hu Penghui,et al."A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition.".INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY 36.(2022)
